Product Information
QELBREE ER 100 MG CAPSULE is a brand product labeled by Supernus Pharmaceuticals Inc., priced at $12.7326 per EA under NDC 17772013130. Its NADAC has been published 259 times since Oct 20, 2021.
FDA first approved this application on Apr 2, 2021.
Strength
100 mg/1
Manufacturer
Supernus Pharmaceuticals Inc.NDC
17772013130
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VILOXAZINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA211964FDA Approved
4/2/2021
On Market Since
4/2/2021
Pharmacological Classes
Price Statistics
The NADAC for QELBREE ER 100 MG CAPSULE has been published 259 times since Oct 20, 2021, and over the history we have for it it has risen 33.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.7326 per EA |
|---|---|
| All-time high | $12.7484 (Jun 10, 2026) |
| All-time low | $9.5697 (Oct 20, 2021) |
| 52-week high | $12.7484 |
| 52-week low | $12.0218 |
| Median price | $11.3469 |
| Average price | $11.2629 |
| Largest weekly change | +6.0% (Jan 3, 2024) |
| Weeks tracked | 259 |
| Tracking since | Oct 20, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the viloxazine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Supernus Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
viloxazine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QELBREE ER 100 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for QELBREE ER 100 MG CAPSULE, manufactured by Supernus Pharmaceuticals Inc., is $12.7326 per EA (NDC 17772013130), effective Sep 30, 2026.
How has the price of QELBREE ER 100 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for QELBREE ER 100 MG CAPSULE has risen 33.1%. It has been tracked across 259 weekly CMS publications since Oct 20, 2021.
What are the highest and lowest recorded NADAC prices for QELBREE ER 100 MG CAPSULE?
Since Oct 20, 2021, the NADAC for QELBREE ER 100 MG CAPSULE has ranged from a low of $9.5697 (Oct 20, 2021) to a high of $12.7484 (Jun 10, 2026), with a median of $11.3469 per EA.
Are there cheaper alternatives to QELBREE ER 100 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of QELBREE ER 100 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures QELBREE ER 100 MG CAPSULE?
QELBREE ER 100 MG CAPSULE (NDC 17772013130) is labeled by Supernus Pharmaceuticals Inc., and CMS classifies it as a brand product.